204688-61-9

Basic information

• Product Name: (S)-1-N-Boc-3-pyrrolidineacetic acid
• Synonyms: (S)-1-N-Boc-3-pyrrolidineacetic acid;(S)-(1-Boc-pyrrolidin-3-yl)acetic acid;(S)-1-Boc-3-pyrrolidineacetic acid;2-[(3S)-1-[(tert-butoxy)carbonyl]pyrrolidin-3-yl]acetic acid;(S)-1-Boc-3-CarboxyMethylpyrrolidine;(S)-2-(1-(tert-Butoxycarbonyl)pyrrolidin-3-yl)acetic acid;3-Pyrrolidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-, (3S)-;(3S)-1-Boc-3-pyrrolidineacetic acid
• CAS NO: 204688-61-9
• Molecular Formula: C₁₁H₁₉NO₄
• Molecular Weight: 229.27
• Mol File: 204688-61-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 357.392 °C at 760 mmHg
• Flash Point: 169.945 °C
• Appearance: /
• Density: 1.151 g/cm³
• Vapor Pressure: 4.5E-06mmHg at 25°C
• Refractive Index: 1.491
• Storage Temp.: 2-8°C
• PKA: 4.65±0.10(Predicted)
• CAS DataBase Reference: (S)-1-N-Boc-3-pyrrolidineacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-N-Boc-3-pyrrolidineacetic acid(204688-61-9)
• EPA Substance Registry System: (S)-1-N-Boc-3-pyrrolidineacetic acid(204688-61-9)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 204688-61-9(Hazardous Substances Data)

Usage

General Description

"(S)-1-N-Boc-3-pyrrolidineacetic acid" is a chemical compound known for its role in organic chemistry, particularly in the synthesis of other complex compounds. Its main structure consists of a pyrrolidine ring, which is a five-membered cyclic amine, coupled with acetic acid and a Boc protecting group. The (S)- enantiomer denotes the specific spatial configuration of the molecule, making it a class of organic compounds known as chiral. The Boc group serves to protect the nitrogen atom in the compound during synthesis procedures, and can be removed under acidic conditions.

InChI:InChI=1/C11H19NO4/c1-11(2,3)16-10(15)12-5-4-8(7-12)6-9(13)14/h8H,4-7H2,1-3H3,(H,13,14)/t8-/m0/s1

Upstream product

• 132945-75-6 (S)-tert-butyl 3-(methylsulfonyloxy)pyrrolidine-1-carboxylate 
• 101469-92-5 (S)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 122442-02-8 (S)-(+)-homo-β-proline 
• 1332331-43-7 5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-4-[4-(6-quinolinyl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1332331-24-4 5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-4-[4-(1H-indol-5-yl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1619968-90-9 (S)-4-(4-(3-chloroquinolin-7-yl)-2-fluorophenyl)-1-methyl-3-((1-propionylpyrrolidin-3-yl)methyl)-1H-1,2,4-triazol-5(4H)-one 
• 1619968-89-6 (S)-4-(2-fluoro-4-(3-methylquinolin-7-yl)phenyl)-1-methyl-3-((1-propionylpyrrolidinyl)methyl)-1H-1,2,4-triazol-5(4H)-one 
• 1619968-97-6 (S)-4-(4-bromo-2-fluorophenyl)-1-methyl-3-((1-propionylpyrrolidin-3-yl)methyl)-1 H-1,2,4-triazol-5(4H)-one 
• 1619968-88-5 (S)-4-(4-(3-chloroquinolin-7-yl)-2-fluorophenyl)-3-((1-propionylpyrrolidin-3-yl)methyl)-1H-1,2,4-triazol-5(4H)-one 
• 1619968-86-3 (S)-4-(2-fluoro-4-(3-fluoroquinolin-7-yl)phenyl)-3-((1-propionylpyrrolidin-3-yl)methyl)-1H-1,2,4-triazol-5(4H)-one 
• 1332333-90-0 4-(4-bromo-2-fluorophenyl)-5-{[(3S)-1-propanoyl-3-pyrrolidinyl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1619968-95-4 N-(4-bromo-2-fluorophenyl)-2-{[(3S)-1-propanoyl-3-pyrrolidinyl]acetyl}hydrazinecarboxamide 
• 808157-27-9 ethyl (S)-(+)-3-pyrrolidineacetate 
• 1619968-79-4 (S)-3-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)methyl)-4-(2-fluoro-4-(3-methylquinolin-7-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one 

Relevant articles and documents

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.